European court ruling on SPCs brings relief to pharma industry
This article was originally published in SRA
The acceptance by the European court of justice of supplementary protection certificates having non-positive terms is welcome news for the innovative pharmaceutical industry, says Mike Snodin.
You may also be interested in...
Richard Pazdur, FDA's oncology chief, reiterates the breakthrough therapy designation is for agency-sponsor communication and not an investor tool.